Form 4: Immunovant CTO Sells Shares for Tax Obligations

Immunovant's Chief Technology Officer, Jay S. Stout, sold 2,520 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Summary

• Jay S. Stout, Chief Technology Officer of Immunovant, Inc. (IMVT), reported a sale of common stock.
• The transaction involved the disposition of 2,520 shares of Immunovant common stock on October 22, 2025.
• The shares were sold at a weighted average price of $19.03 per share, with individual transactions ranging from $19.03 to $19.23.
• The sale was executed to cover tax withholding obligations associated with the vesting and settlement of 6,250 restricted stock units (RSUs) that vested on October 17, 2025.
• These RSUs were part of a larger grant of 100,000 RSUs awarded on April 17, 2023.
• Following this transaction, Jay S. Stout beneficially owns 200,814 shares of Immunovant common stock.
• The sale was mandated by Immunovant's policy requiring tax withholding obligations to be funded by a 'sell to cover' transaction and was not a discretionary decision by the Reporting Person.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transaction is a routine, non-discretionary sale for tax purposes related to RSU vesting, which does not reflect a change in management's confidence or the company's fundamentals.

Positives

• The sale was non-discretionary and mandated by the issuer's policy for tax withholding, indicating it was not a voluntary sale driven by a lack of confidence in the company.
• The transaction is a routine event related to RSU vesting, reflecting standard compensation practices.

Negatives

• Any insider selling, even for tax purposes, can sometimes be misinterpreted by the market as a negative signal, potentially leading to short-term negative sentiment.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the scheduled vesting of RSUs.

Management Comments

• The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
• The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

This transaction is a routine insider filing common across publicly traded companies, reflecting standard executive compensation practices involving restricted stock units and the associated tax obligations upon vesting. 'Sell to cover' is a widely adopted mechanism for satisfying these tax liabilities.

Comparison to Industry Standards

• The 'sell to cover' mechanism for satisfying tax withholding obligations on vested restricted stock units is a standard practice across most industries and companies, including those in the biotechnology and pharmaceutical sectors like Immunovant.
• This method is commonly used by companies such as Moderna, Pfizer, and Biogen, where executives receive equity compensation that vests over time, leading to similar non-discretionary sales for tax purposes.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine, non-discretionary transaction for tax purposes, not indicative of a change in company fundamentals or insider sentiment.
• Employees: No direct impact mentioned, but it reflects standard equity compensation practices for executives.

Key Dates

Recommendation

The transaction reported is a routine, non-discretionary 'sell to cover' sale by an executive to satisfy tax obligations upon RSU vesting. It does not signal a change in the company's fundamental outlook or the executive's confidence. Therefore, it provides no new information that would warrant a change in investment recommendation; a 'hold' stance is appropriate based solely on this filing.

Keywords

Immunovant, IMVT, Jay S. Stout, Chief Technology Officer, Insider Trading, Form 4, Restricted Stock Units, RSU Vesting, Sell to Cover, Tax Withholding, Common Stock